Previous 10 | Next 10 |
Geneva, Switzerland and Boston, MA – July 8, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductiv...
ObsEva SA (NASDAQ: OBSV ) appoints Dr. Elizabeth Garner as its new Chief Medical Officer (CMO) and member of the Executive Committee, effective July 15. Dr. Garner will be based in the US. More news on: ObsEva SA, Healthcare stocks news, Read more ...
Geneva, Switzerland and Boston, MA – July 1, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s ...
Gainers: Axovant Gene Therapies (NASDAQ: AXGT ) +40% . ContraVir Pharmaceuticals (NASDAQ: CTRV ) +24% . India Globalization Capital (NYSEMKT: IGC ) +17% . Pintec Technology (NASDAQ: PT ) +14% . ObsEva SA (NASDAQ: OBSV ) +12% . Overstock.com (NASDAQ: OSTK ) +12% . Fuwei Films (NASDAQ...
Geneva, Switzerland and Boston, MA – June 21, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive heal...
ObsEva (NASDAQ: OBSV ) announces that its recent End-of-Phase 2 (EOP2) meeting with the FDA provided clarification on key development issues for its oral oxytocin receptor antagonist nolasiban. More news on: ObsEva SA, Healthcare stocks news, Read more ...
Geneva, Switzerland and Boston, MA – June 19, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive h...
The following slide deck was published by ObsEva SA in conjunction with this Read more ...
Geneva, Switzerland and Boston, MA – June 4, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductiv...
ObsEva SA (OBSV) Q1 2019 Results Earnings Conference Call May 09, 2019 08:00 AM ET Company Participants Mario Corso - Senior Director, Investor Relations Ernest Loumaye - Co-Founder and Chief Executive Officer Jean-Pierre Gotteland - Chief Scientific Officer Wim Souverijns - Ch...
News, Short Squeeze, Breakout and More Instantly...
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – April 3, 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced that the Regulatory ...
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – March 18, 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced that, concurr...
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – 28 February 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for women's health, today announced that it will wind-down its operati...